• Zai Lab won EMA orphan drug designation for DLL3-targeting ADC zocilurtatug pelitecan (Zoci) in pulmonary neuroendocrine carcinomas.
• EMA committee cited early relapsed or refractory extensive-stage SCLC data, flagging durable responses versus authorized therapies as a clinically relevant advantage.
• Zoci previously secured FDA Fast Track status and orphan drug designation for SCLC; Fast Track also granted for extrapulmonary neuroendocrine carcinomas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260616338405) on June 16, 2026, and is solely responsible for the information contained therein.